Skip to main content
Midas Edge

Edgewise Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

EWTX$46.53-4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

STATEMENTS OF AND STOCKHOLDERS’ EQUITY

STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Other · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common Stock · ​ · Additional · ​ · Comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Paid-In Capital · ​ ​ ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Total
Balance as of December 31, 2022​63,257,376​$6​$492,665​$(1,355)​$(144,600)​$346,716
Issuance of common stock, net of offering costs6,928,044​​1​​52,549​​—​—​52,550
Exercise of stock options and vesting of restricted stock units172,663​​—​​117​​—​—​117
Purchase of common stock under employee stock purchase plan​95,259​​—​​596​​—​—​596
Stock-based compensation​—​​—​​17,560​​—​—​17,560
Other comprehensive income​—​​—​​—​​1,454​—​1,454
Net loss—​​—​​—​​—​(100,163)​(100,163)
Balance as of December 31, 2023​70,453,342​$7​$563,487​$99​$(244,763)​$318,830
Issuance of common stock, net of offering costs​22,450,206​​2​​238,797​​—​​—​​238,799
Exercise of stock options and vesting of restricted stock units​1,787,832​​—​​9,480​​—​​—​​9,480
Purchase of common stock under employee stock purchase plan​147,086​​—​​888​​—​​—​​888
Stock-based compensation​—​​—​​24,711​​—​​—​​24,711
Other comprehensive income​—​​—​​—​​321​​—​​321
Net loss​—​​—​​—​​—​​(133,813)​​(133,813)
Balance as of December 31, 2024​94,838,466​$9​$837,363​$420​$(378,576)​$459,216
Issuance of common stock, net of offering costs​9,935,419​​1​​187,100​​—​​—​​187,101
Exercise of stock options and vesting of restricted stock units​1,400,533​​—​​7,803​​—​​—​​7,803
Purchase of common stock under employee stock purchase plan​75,161​​—​​923​​—​​—​​923
Stock-based compensation​—​​—​​34,752​​—​​—​​34,752
Other comprehensive income​—​​—​​—​​257​​—​​257
Net loss​—​​—​​—​​—​​(167,795)​​(167,795)
Balance as of December 31, 2025​106,249,579​$10​$1,067,941​$677​$(546,371)​$522,257
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.